Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD OTCMKTS:HBPCF NASDAQ:TIL NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.60+1.3%$11.52$4.88▼$19.58$186.59MN/A87,039 shs139,793 shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$45.83M-0.05418 shsN/ATILInstil Bio$31.50+3.9%$26.86$10.80▼$92.00$212.65M2.1699,744 shs185,281 shsTVGNTevogen Bio$0.87-1.5%$1.05$0.26▼$3.09$170.43M-0.78636,483 shs543,280 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+1.30%+3.61%-31.58%-27.18%+859,999,900.00%HBPCFHelix Biopharma0.00%0.00%0.00%0.00%-22.63%TILInstil Bio+3.89%+16.67%+19.73%-4.23%+113.70%TVGNTevogen Bio-1.47%-4.79%-9.03%-39.41%+82.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.60+1.3%$11.52$4.88▼$19.58$186.59MN/A87,039 shs139,793 shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$45.83M-0.05418 shsN/ATILInstil Bio$31.50+3.9%$26.86$10.80▼$92.00$212.65M2.1699,744 shs185,281 shsTVGNTevogen Bio$0.87-1.5%$1.05$0.26▼$3.09$170.43M-0.78636,483 shs543,280 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+1.30%+3.61%-31.58%-27.18%+859,999,900.00%HBPCFHelix Biopharma0.00%0.00%0.00%0.00%-22.63%TILInstil Bio+3.89%+16.67%+19.73%-4.23%+113.70%TVGNTevogen Bio-1.47%-4.79%-9.03%-39.41%+82.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$32.60279.07% UpsideHBPCFHelix Biopharma 0.00N/AN/AN/ATILInstil Bio 3.00Buy$119.00277.78% UpsideTVGNTevogen Bio 3.00Buy$10.001,054.20% UpsideCurrent Analyst Ratings BreakdownLatest HBPCF, TIL, AARD, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/28/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $25.008/27/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/15/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.00 ➝ $125.008/14/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $19.008/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/30/2025AARDAardvark TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/10/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/AHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%9/8/2025 (Estimated)TILInstil Bio-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)TVGNTevogen Bio-$13.73MN/A0.00∞N/AN/AN/A-775.49%11/10/2025 (Estimated)Latest HBPCF, TIL, AARD, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/13/2025Q2 2025AARDAardvark Therapeutics-$0.52-$0.66-$0.14-$0.66N/AN/A8/13/2025Q2 2025TILInstil Bio-$1.72-$3.24-$1.52-$3.24N/AN/A6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A14.0414.04HBPCFHelix BiopharmaN/A0.420.42TILInstil Bio0.6414.9714.97TVGNTevogen BioN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AHBPCFHelix BiopharmaN/ATILInstil Bio60.56%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AHBPCFHelix Biopharma7.60%TILInstil Bio47.20%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AHBPCFHelix Biopharma976.38 million70.57 millionNot OptionableTILInstil Bio4106.75 million3.57 millionNo DataTVGNTevogen Bio3196.71 million52.64 millionN/AHBPCF, TIL, AARD, and TVGN HeadlinesRecent News About These CompaniesTevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 6 at 8:54 AM | marketbeat.comTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on ...September 4 at 6:02 PM | bakersfield.comBTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and LymphomasSeptember 4 at 3:48 PM | globenewswire.comTevogen Bio Highlights Promising Clinical Results for TVGN 489 in Treating SARS-CoV-2 in Immunocompromised PatientsSeptember 3 at 4:31 PM | quiverquant.comQTevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2September 3 at 4:15 PM | globenewswire.comTevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 28, 2025 | finanznachrichten.deTevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term ValueAugust 27, 2025 | quiverquant.comQTevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 27, 2025 | globenewswire.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityAugust 26, 2025 | markets.businessinsider.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityAugust 26, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025August 25, 2025 | quiverquant.comQTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsAugust 25, 2025 | globenewswire.comTevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | markets.businessinsider.comTevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and InnovationAugust 22, 2025 | quiverquant.comQTevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Announces Earnings ResultsAugust 21, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)August 20, 2025 | marketbeat.comTevogen finalizes agreement for up to $50M in financingAugust 19, 2025 | msn.comREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...August 19, 2025 | bakersfield.comBREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsAugust 19, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth StrategyAugust 19, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Jackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Lowe’s Builds Value for Investors: Still a Good Buy in 2025By Thomas Hughes | August 20, 2025Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?By Ryan Hasson | August 9, 2025HBPCF, TIL, AARD, and TVGN Company DescriptionsAardvark Therapeutics NASDAQ:AARD$8.60 +0.11 (+1.30%) As of 09/5/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 09/5/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Instil Bio NASDAQ:TIL$31.50 +1.18 (+3.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$31.55 +0.05 (+0.16%) As of 09/5/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Tevogen Bio NASDAQ:TVGN$0.87 -0.01 (-1.47%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.39%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
